Lowie E.G.W. Vanfleteren

1 month ago | publications.ersnet.org | Jorine Hartman |Marnix Jonker |Rein Posthuma |Lowie E.G.W. Vanfleteren

IntroductionBronchoscopic lung volume reduction using endobronchial valves (EBV) has been shown to provide clinical benefits for patients with emphysema including improvements in lung function, exercise capacity, dyspnoea severity and quality of life [1]. Recently, there has been increased attention on the potential extrapulmonary effects of this treatment.

Feb 17, 2024 | resmedjournal.com | Rein Posthuma |Jorine Hartman |Martijn A. Spruit |Dirk-Jan Slebos |Lowie E.G.W. Vanfleteren |Anouk W. Vaes

Patients with advanced emphysema eligible for bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV) are characterized by severe static lung hyperinflation, which can be considered a treatable trait. Other treatable traits (TTs), which are assumed to be present in this highly selected patient group, have not been studied in detail nor how they may affect health-related quality of life (HRQL).

Jul 2, 2023 | resmedjournal.com | Malin Axelsson |Helena Backman |Bright I Nwaru |Caroline Stridsman |Lowie E.G.W. Vanfleteren |Linnea Hedman | +8 more